RxDoctor Payments Data

Alyxandra Yankaskas, PA

Physician Assistant · Pearland, TXNPI 1912533910

Payments from drug & device makers

$19,101in general payments, 2019–2025

Across 903 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Johnson & Johnson$2K
  • Galderma Laboratories, L.p.$1K
  • Sanofi$1K
  • Novartis$1K
  • plus $8K from 27 others

What the payments were for

  • Speaking & faculty fees$790%
  • Food & beverage$18,28496%
  • Education$7384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,101 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$72,405
Medicare patients
228
Services billed
1,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast28$131,430
Dupixent PenDupilumab17$65,888
JubliaEfinaconazole24$17,579
Clobetasol Propionate106$3,581
Ketoconazole140$2,645
Tacrolimus14$2,028
Azelaic Acid11$943
Triamcinolone Acetonide94$701
Doxycycline Hyclate50$560
Ciclopirox14$458
ValacyclovirValacyclovir Hcl16$430
Fluocinonide11$352
Hydrocortisone41$200
Mupirocin19$117
Minoxidil19$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$512$131,43028 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$588$17,57924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →